CORRIGENDUM FOR "Hemodynamic Markers and Subclinical Atherosclerosis in Postmenopausal Women With Primary Hyperparathroidism".

08:00 EDT 1st April 2019 | BioPortfolio

Summary of "CORRIGENDUM FOR "Hemodynamic Markers and Subclinical Atherosclerosis in Postmenopausal Women With Primary Hyperparathroidism"."

No Summary Available


Journal Details

This article was published in the following journal.

Name: The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197


DeepDyve research library

PubMed Articles [9921 Associated PubMed Articles listed on BioPortfolio]

Women with Preterm Birth Have Evidence of Subclinical Atherosclerosis a Decade After Delivery.

Women with preterm birth (PTB) have excess risk of cardiovascular disease (CVD) and metabolic dysregulation after delivery, but vascular mechanisms are poorly understood. We considered that women with...

Subclinical atherosclerosis in psoriatic disease: relation to endocan, TNF-α, age of onset, and body fat.

Psoriasis is a common multisystem inflammatory disease with several associated comorbidities. Serological markers to detect associated subclinical atherosclerosis in psoriatic patients are needed. We ...

Effect of high-intensity interval training on body composition and inflammatory markers in obese postmenopausal women: a randomized controlled trial.

This study tested whether high-intensity interval training is a time-efficient strategy for improving visceral adiposity tissue and inflammatory markers in obese postmenopausal women when compared wit...

The Acute Effects of Mat Pilates on Hemodynamic and Salivary Nitrate Responses After Exercise in Postmenopausal Women.

The aim of study was to compare the hemodynamic and salivary responses after Mat Pilates, aerobic, resistance exercise and control. 16 normotensive postmenopausal women performed: PILATES:ten floor ex...

The Barcelona-Asymptomatic Intracranial Atherosclerosis study: Subclinical intracranial atherosclerosis as predictor of long-term vascular events.

Symptomatic intracranial atherosclerosis (ICAS) is associated with a high risk of stroke recurrence and occurrence of other vascular events. However, ICAS has been poorly studied from its asymptomatic...

Clinical Trials [8979 Associated Clinical Trials listed on BioPortfolio]

EPAT: Estrogen in the Prevention of Atherosclerosis Trial

The purpose of this study is to determine the effects of estrogen replacement therapy (ERT) on the progression of early atherosclerosis in healthy postmenopausal women without preexisting ...

Estrogen Exposure and Atherosclerosis in Postmenopausal Women

One hundred Spanish postmenopausal women accepted to be investigated for cardiovascular risk actors including clinical features, serum biochemical parameters, single nucleotide polymorphis...

Estrogen Replacement and Atherosclerosis (ERA) in Older Women

To determine if estrogen replacement therapy, with or without low dose progesterone, slows progression or induces regression of coronary atherosclerosis in postmenopausal women.

Study of Anti-atherosclerotic Activity of Karinat in Postmenopausal Women

The purpose of this study is to investigate the anti-atherosclerotic action of natural drug Karinat based on phytoestrogen-rich botanicals in postmenopausal women.

Soy and Lipoproteins in Postmenopausal Women

To determine the effects of soy on lipids, lipoproteins and lipoprotein subclass in a sample of African-American and white postmenopausal women with low-density lipoprotein (LDL) cholester...

Medical and Biotech [MESH] Definitions

A gonadal stromal neoplasm composed only of THECA CELLS, occurring mostly in the postmenopausal OVARY. It is filled with lipid-containing spindle cells and produces ESTROGENS that can lead to ENDOMETRIAL HYPERPLASIA; UTERINE HEMORRHAGE; or other malignancies in postmenopausal women and sexual precocity in girls. When tumors containing theca cells also contain FIBROBLASTS, they are identified as thecoma-fibroma tumors with less active hormone production.

A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.

Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.

An aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone, a major mammalian estrogen. It is converted from ANDROSTENEDIONE directly, or from TESTOSTERONE via ESTRADIOL. In humans, it is produced primarily by the cyclic ovaries, PLACENTA, and the ADIPOSE TISSUE of men and postmenopausal women.

A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.

Quick Search


DeepDyve research library

Relevant Topic

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Searches Linking to this Article